178 related articles for article (PubMed ID: 35690772)
1. Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer.
Wang H; Fan L; Wu X; Han Y
BMC Womens Health; 2022 Jun; 22(1):224. PubMed ID: 35690772
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Takaya H; Nakai H; Murakami K; Tobiume T; Suzuki A; Mandai M; Matsumura N
Int J Clin Oncol; 2018 Aug; 23(4):698-706. PubMed ID: 29572761
[TBL] [Abstract][Full Text] [Related]
4. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
5. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.
Yang X; Fu C
Arch Gynecol Obstet; 2022 Nov; 306(5):1417-1429. PubMed ID: 35165749
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
Vrdoljak J; Boban T; Petrić Miše B; Boraska Jelavić T; Bajić Ž; Tomić S; Vrdoljak E
Jpn J Clin Oncol; 2019 Apr; 49(4):347-353. PubMed ID: 30796833
[TBL] [Abstract][Full Text] [Related]
7. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
9. First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.
Parisi A; Palluzzi E; Cortellini A; Sidoni T; Cocciolone V; Lanfiuti Baldi P; Porzio G; Ficorella C; Cannita K
Clin Transl Oncol; 2020 Jan; 22(1):158-162. PubMed ID: 31041717
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
Wang L; Li S; Zhu D; Qin Y; Wang X; Hong Z; Han Z
J Gynecol Oncol; 2023 Jul; 34(4):e44. PubMed ID: 36807747
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
[TBL] [Abstract][Full Text] [Related]
13. Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer.
Kim YN; Lee YJ; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2020 Mar; 31(2):e23. PubMed ID: 31912678
[TBL] [Abstract][Full Text] [Related]
14. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
[TBL] [Abstract][Full Text] [Related]
16. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
[TBL] [Abstract][Full Text] [Related]
19. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]